Welltower Inc. (WELL) stock
Close on Oct 30, 2026Market cap $169.09BP/E 107.6Yield 1.20%
Earnings
Welltower's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Welltower's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 9, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 26, 2026after the close | $3.72B | +38.4% | $0.54 | $1.67 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 27, 2026during market hours | $3.54B | – | $0.61 | $1.60 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 28, 2026during market hours | $3.35B | +38.3% | $1.02 | $1.47 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 10, 2026during market hours | $3.18B | +41.3% | $0.14 | $1.45 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 27, 2025during market hours | $2.69B | +30.6% | $0.41 | $1.34 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 28, 2025during market hours | – | – | $0.45 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 28, 2025during market hours | $2.42B | +30.3% | $0.40 | $1.20 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 11, 2025during market hours | $2.25B | +28.6% | $0.19 | $1.13 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 28, 2024during market hours | $2.06B | +23.7% | $0.73 | $1.11 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 29, 2024during market hours | $1.82B | +9.6% | $0.42 | $1.05 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 29, 2024during market hours | $1.86B | +19.2% | $0.22 | $1.01 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 13, 2024during market hours | $1.75B | +15.2% | $0.15 | $0.96 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 30, 2023during market hours | $1.66B | +12.8% | $0.24 | $0.92 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 31, 2023during market hours | $1.67B | +13.1% | $0.20 | $0.90 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 2, 2023during market hours | $1.56B | +11.8% | $0.05 | $0.85 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 15, 2023during market hours | $1.52B | +16.0% | -$0.01 | $0.83 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022during market hours | $1.47B | +18.9% | -$0.01 | $0.84 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022during market hours | $1.47B | – | $0.20 | $0.86 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022during market hours | $1.40B | – | $0.14 | $0.82 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 15, 2022during market hours | $1.31B | – | $0.13 | $0.83 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021during market hours | $1.24B | – | $0.42 | $0.80 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021during market hours | – | – | – | – | Release |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021during market hours | – | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Feb 9, 2021during market hours | – | – | – | – | Release |
| Q3 FY2020ended Sep 30, 2020 | Oct 28, 2020during market hours | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Welltower's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| average blended SSNOI growthnon-GAAP | FY2026 | +15% – +16.25% | – | New | Oct 26, 2026 |
| Net income attributable to common stockholdersGAAP | FY2026 | $3.31 – $3.37 | – | New | Oct 26, 2026 |
| Net income attributable to common stockholdersGAAP | FY2026 | $3.11 – $3.19 | $3.24 – $3.38 | Lowered | Jul 27, 2026 |
| full year normalized FFO attributable to common stockholdersnon-GAAP | FY2026 | $6.47 – $6.53 | – | New | Oct 26, 2026 |
| full year normalized FFO attributable to common stockholdersnon-GAAP | FY2026 | $6.36 – $6.44 | $6.21 – $6.35 | Raised | Jul 27, 2026 |
| funding an additional development | FY2026 | $370.00M | – | New | Feb 10, 2026 |
| average blended SSNOI growthnon-GAAP | FY2026 | +13.75% – +16% | +12.25% – +16% | Raised | Jul 27, 2026 |
| general and administrative expenses | FY2026 | $265.00M – $270.00M | $263.00M – $271.00M | Raised | Jul 27, 2026 |
| Long-Term/Post-Acute Care SSNOI growthnon-GAAP | FY2026 | +2% – +3% | – | Reaffirmed | Apr 28, 2026 |
| Outpatient Medical SSNOI growthnon-GAAP | FY2026 | +2% – +3% | – | Lowered | Apr 28, 2026 |
| Seniors Housing Operating SSNOI growthnon-GAAP | FY2026 | +16.5% – +21.5% | – | Raised | Apr 28, 2026 |
| Seniors Housing Triple-net SSNOI growthnon-GAAP | FY2026 | +3% – +4% | – | Lowered | Apr 28, 2026 |
| stock-based compensation expense | FY2026 | $60.00M | $60.00M | Lowered | Jul 27, 2026 |
Guidance vs results
The last range Welltower gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | EPS (GAAP) | $0.82 – $0.88 | $1.40Σ4Q | Above range |
| Q4 FY2022 | EPS (GAAP) | $0.08 – $0.13 | -$0.01 | Below range |
| Q4 FY2022 | normalized FFO attributable to common stockholders | $0.80 – $0.85 | $0.83 | Within range |
| Q3 FY2022 | EPS (GAAP) | $0.12 – $0.17 | -$0.01 | Below range |
| Q3 FY2022 | normalized FFO attributable to common stockholders | $0.82 – $0.87 | $0.84 | Within range |
| Q2 FY2022 | EPS (GAAP) | $0.20 – $0.25 | $0.20 | Within range |
| Q2 FY2022 | normalized FFO attributable to common stockholders | $0.82 – $0.87 | $0.86 | Within range |
| Q1 FY2022 | EPS (GAAP) | $0.17 – $0.22 | $0.14 | Below range |
| Q1 FY2022 | normalized FFO attributable to common stockholders | $0.79 – $0.84 | $0.82 | Within range |
| Q4 FY2021 | EPS (GAAP) | $0.20 – $0.25 | $0.13 | Below range |
| Q4 FY2021 | normalized FFO attributable to common stockholders | $0.78 – $0.83 | $0.83 | Within range |
Guidance history
Every forecast Welltower put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 26, 2026 | average blended SSNOI growth | FY2026 | +15% – +16.25% | New |
| Oct 26, 2026 | full year normalized FFO attributable to common stockholders | FY2026 | $6.47 – $6.53 | New |
| Oct 26, 2026 | Net income attributable to common stockholders | FY2026 | $3.31 – $3.37 | New |
| Jul 27, 2026 | full year normalized FFO attributable to common stockholders | FY2026 | $6.36 – $6.44 | Raised |
| Jul 27, 2026 | Net income attributable to common stockholders | FY2026 | $3.11 – $3.19 | Lowered |
| Jul 27, 2026 | general and administrative expenses | FY2026 | $265.00M – $270.00M | Raised |
| Jul 27, 2026 | average blended SSNOI growth | FY2026 | +13.75% – +16% | Raised |
| Jul 27, 2026 | stock-based compensation expense | FY2026 | $60.00M | Lowered |
| Apr 28, 2026 | full year normalized FFO attributable to common stockholders per diluted share | FY2026 | $6.21 – $6.35 | Raised |
| Apr 28, 2026 | Net income attributable to common stockholders per diluted share | FY2026 | $3.24 – $3.38 | Raised |
| Apr 28, 2026 | pro rata disposition proceeds | the next twelve months | $1.40B | – |
| Apr 28, 2026 | average blended SSNOI growth | FY2026 | +12.25% – +16% | Raised |
| Apr 28, 2026 | Seniors Housing Operating SSNOI growth | FY2026 | +16.5% – +21.5% | Raised |
| Apr 28, 2026 | Seniors Housing Triple-net SSNOI growth | FY2026 | +3% – +4% | Lowered |
| Apr 28, 2026 | Outpatient Medical SSNOI growth | FY2026 | +2% – +3% | Lowered |
| Apr 28, 2026 | Long-Term/Post-Acute Care SSNOI growth | FY2026 | +2% – +3% | Reaffirmed |
| Apr 28, 2026 | general and administrative expenses | FY2026 | $263.00M – $271.00M | Raised |
| Apr 28, 2026 | stock-based compensation expense | FY2026 | $60.00M | Lowered |
| Feb 10, 2026 | funding an additional development | FY2026 | $370.00M | New |
| Feb 10, 2026 | normalized FFO attributable to common stockholders per diluted share | FY2026 | $6.09 – $6.25 | New |
| Feb 10, 2026 | net income attributable to common stockholders per diluted share | FY2026 | $3.11 – $3.27 | New |
| Feb 10, 2026 | average blended SSNOI growth | FY2026 | +11.25% – +15.75% | New |
| Feb 10, 2026 | general and administrative expenses | FY2026 | $260.00M – $270.00M | New |
| Oct 27, 2025 | development funding | FY2025 | $80.00M | Lowered |
| Oct 27, 2025 | average blended SSNOI growth | FY2025 | +13.2% – +14.5% | New |
| Oct 27, 2025 | Seniors Housing Operating SSNOI growth | FY2025 | +20.5% – +22% | Raised |
| Oct 27, 2025 | Seniors Housing Triple-net SSNOI growth | FY2025 | +3.5% – +4.5% | Lowered |
| Oct 27, 2025 | Outpatient Medical SSNOI growth | FY2025 | +2% – +3% | Lowered |
| Oct 27, 2025 | Long-Term/Post-Acute Care SSNOI growth | FY2025 | +2% – +3% | Reaffirmed |
| Oct 27, 2025 | normalized FFO attributable to common stockholders | FY2025 | $5.24 – $5.30 | New |
| Oct 27, 2025 | Net income attributable to common stockholders | FY2025 | $0.82 – $0.88 | Lowered |
| Oct 27, 2025 | general and administrative expenses | FY2025 | $243.00M – $249.00M | Raised |
| Oct 27, 2025 | stock-based compensation expense | FY2025 | $52.00M | Lowered |
| Oct 27, 2025 | pro rata disposition proceeds | in the next twelve months | $9.00B | – |
| Jul 28, 2025 | development funding | FY2025 | $212.00M | New |
| Jul 28, 2025 | Net income attributable to common stockholders | FY2025 | $1.86 – $1.94 | New |
| Jul 28, 2025 | average blended SSNOI growth | FY2025 | +11.25% – +13.25% | New |
| Jul 28, 2025 | Seniors Housing Operating SSNOI growth | FY2025 | +18.5% – +21.5% | Raised |
| Jul 28, 2025 | pro rata disposition proceeds | next twelve months | $340.00M | – |
| Jul 28, 2025 | Seniors Housing Triple-net SSNOI growth | FY2025 | +3.5% – +4.5% | Lowered |
| Jul 28, 2025 | Outpatient Medical SSNOI growth | FY2025 | +2% – +3% | Lowered |
| Jul 28, 2025 | Long-Term/Post-Acute Care SSNOI growth | FY2025 | +2% – +3% | Reaffirmed |
| Jul 28, 2025 | general and administrative expenses | FY2025 | $243.00M – $249.00M | New |
| Jul 28, 2025 | stock-based compensation expense | FY2025 | $52.00M | Lowered |
| Apr 28, 2025 | funding an additional $340 million of development | FY2025 | $340.00M | Lowered |
| Apr 28, 2025 | Net income attributable to common stockholders guidance | FY2025 | $1.70 – $1.84 | Raised |
| Apr 28, 2025 | Outpatient Medical | FY2025 | +2% – +3% | Lowered |
| Apr 28, 2025 | pro rata disposition proceeds | in the next twelve months | $166.00M | – |
| Apr 28, 2025 | average blended SSNOI growth | FY2025 | +10% – +13.25% | Raised |
| Apr 28, 2025 | Seniors Housing Operating | FY2025 | +16.5% – +21.5% | Raised |
| Apr 28, 2025 | Seniors Housing Triple-net | FY2025 | +3% – +4% | Lowered |
| Apr 28, 2025 | Long-Term/Post-Acute Care | FY2025 | +2% – +3% | Reaffirmed |
| Apr 28, 2025 | general and administrative expenses | FY2025 | $240.00M – $250.00M | Raised |
| Apr 28, 2025 | stock-based compensation expense | FY2025 | $51.00M | Lowered |
| Apr 28, 2025 | full year normalized FFO attributable to common stockholders | FY2025 | $4.90 – $5.04 | New |
| Feb 11, 2025 | funding an additional development in 2025 relating to projects underway as of December 31, 2024 | FY2025 | $461.00M | New |
| Feb 11, 2025 | normalized FFO attributable to common stockholders | FY2025 | $4.79 – $4.95 | New |
| Feb 11, 2025 | net income attributable to common stockholders | FY2025 | $1.60 – $1.76 | New |
| Feb 11, 2025 | average blended SSNOI growth | FY2025 | +9.25% – +13% | New |
| Feb 11, 2025 | Seniors Housing Operating SSNOI growth | FY2025 | +15% – +21% | Raised |
| Feb 11, 2025 | Seniors Housing Triple-net SSNOI growth | FY2025 | +3% – +4% | Lowered |
| Feb 11, 2025 | Outpatient Medical SSNOI growth | FY2025 | +2% – +3% | Lowered |
| Feb 11, 2025 | Long-Term/Post-Acute Care SSNOI growth | FY2025 | +2% – +3% | Reaffirmed |
| Feb 11, 2025 | general and administrative expenses | FY2025 | $235.00M – $245.00M | New |
| Feb 11, 2025 | stock-based compensation expense | FY2025 | $49.00M | Lowered |
| Feb 11, 2025 | pro rata disposition proceeds | the next twelve months | $516.00M | – |
| Oct 28, 2024 | funding an additional development in 2024 | FY2024 | $247.00M | New |
| Oct 28, 2024 | normalized FFO attributable to common stockholders | FY2024 | $4.27 – $4.33 | Raised |
| Oct 28, 2024 | Net income attributable to common stockholders | FY2024 | $1.75 – $1.81 | Raised |
| Oct 28, 2024 | average blended SSNOI growth | FY2024 | +11.5% – +13% | New |
| Oct 28, 2024 | Seniors Housing Operating SSNOI growth | FY2024 | +22% – +24% | Raised |
| Oct 28, 2024 | Seniors Housing Triple-net SSNOI growth | FY2024 | +4% – +5% | Lowered |
| Oct 28, 2024 | Outpatient Medical SSNOI growth | FY2024 | +2% – +3% | Lowered |
| Oct 28, 2024 | Long-Term/Post-Acute Care SSNOI growth | FY2024 | +2% – +3% | Reaffirmed |
| Oct 28, 2024 | general and administrative expenses | FY2024 | $205.00M – $211.00M | New |
| Oct 28, 2024 | stock-based compensation expense | FY2024 | $40.00M | Lowered |
| Oct 28, 2024 | pro rata disposition proceeds | in the next twelve months | $899.00M | – |
| Jul 29, 2024 | full year normalized FFO attributable to common stockholders | FY2024 | $4.13 – $4.21 | Raised |
| Jul 29, 2024 | Net income attributable to common stockholders | FY2024 | $1.52 – $1.60 | Narrowed |
| Apr 29, 2024 | full year normalized FFO attributable to common stockholders | FY2024 | $4.02 – $4.15 | Raised |
| Apr 29, 2024 | N et income attributable to common stockholders | FY2024 | $1.48 – $1.61 | Raised |
| Feb 13, 2024 | average blended SSNOI growth | FY2024 | +8.25% – +11.5% | New |
| Feb 13, 2024 | normalized FFO attributable to common stockholders | FY2024 | $3.94 – $4.10 | New |
| Feb 13, 2024 | net income attributable to common stockholders | FY2024 | $1.21 – $1.37 | New |
| Oct 30, 2023 | normalized FFO attributable to common stockholders | FY2023 | $3.59 – $3.63 | Raised |
| Oct 30, 2023 | net income attributable to common stockholders | FY2023 | $0.91 – $0.95 | Raised |
| Jul 31, 2023 | normalized FFO attributable to common stockholders | FY2023 | $3.48 – $3.59 | Raised |
| Jul 31, 2023 | net income attributable to common stockholders | FY2023 | $0.73 – $0.84 | Raised |
| May 2, 2023 | normalized FFO attributable to common stockholders | FY2023 | $3.39 – $3.54 | Raised |
| May 2, 2023 | net income attributable to common stockholders | FY2023 | $0.57 – $0.72 | Lowered |
| May 2, 2023 | average blended SSNOI growth | FY2023 | +9% – +13% | New |
| Feb 15, 2023 | normalized FFO attributable to common stockholders | FY2023 | $3.35 – $3.53 | New |
| Feb 15, 2023 | net income attributable to common stockholders | FY2023 | $0.57 – $0.75 | New |
| Nov 7, 2022 | normalized FFO attributable to common stockholders | Q4 FY2022 | $0.80 – $0.85 | New |
| Nov 7, 2022 | net income attributable to common stockholders | Q4 FY2022 | $0.08 – $0.13 | New |
| Aug 9, 2022 | normalized FFO attributable to common stockholders | Q3 FY2022 | $0.82 – $0.87 | New |
| Aug 9, 2022 | net income attributable to common stockholders | Q3 FY2022 | $0.12 – $0.17 | New |
| May 10, 2022 | development | FY2022 | $673.00M | New |
| May 10, 2022 | average blended SSNOI growth | Q2 FY2022 | +8% – +10% | New |
| May 10, 2022 | normalized FFO attributable to common stockholders | Q2 FY2022 | $0.82 – $0.87 | New |
| May 10, 2022 | net income attributable to common stockholders | Q2 FY2022 | $0.20 – $0.25 | New |
| May 10, 2022 | Seniors Housing Operating | Q2 FY2022 | +15% – +20% | New |
| May 10, 2022 | Seniors Housing Triple-net | Q2 FY2022 | +7% – +8% | Lowered |
| May 10, 2022 | Outpatient Medical | Q2 FY2022 | +2% – +3% | Lowered |
| May 10, 2022 | Health System | Q2 FY2022 | +2.75% | Narrowed |
| May 10, 2022 | Long-Term/Post-Acute Care | Q2 FY2022 | +2% – +3% | Lowered |
| May 10, 2022 | Provider Relief Funds | Q2 FY2022 | $6.00M | New |
| May 10, 2022 | general and administrative expenses | Q2 FY2022 | $35.00M – $37.00M | Raised |
| May 10, 2022 | stock-based compensation expense | Q2 FY2022 | $6.00M | Lowered |
| May 10, 2022 | pro rata disposition proceeds and loan payoffs | next twelve months | $352.00M | – |
| May 10, 2022 | blended yield | next twelve months | 6.8% | – |
| Feb 15, 2022 | normalized FFO attributable to common stockholders | Q1 FY2022 | $0.79 – $0.84 | New |
| Feb 15, 2022 | net income attributable to common stockholders | Q1 FY2022 | $0.17 – $0.22 | New |
| Nov 4, 2021 | normalized FFO attributable to common stockholders | Q4 FY2021 | $0.78 – $0.83 | New |
| Nov 4, 2021 | net income attributable to common stockholders | Q4 FY2021 | $0.20 – $0.25 | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Welltower filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results